CClinicalTrials.gg
TerminatedNCT03609073Updated Nov 24, 2021

Endomina Diverticulum

An interventional study of Endomina in Oesophageal Disease, sponsored by Erasme University Hospital. Terminated at 1 site in Belgium. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by Erasme University Hospital · Not applicable, Interventional, and Treatment

Why this study was terminated
enrollment too slow
Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Esophageal diverticulum is a rare disease. Majority comes form the pharyngo-esophageal junction (70 % Zenker's Diverticulum), 10% are mediothoracic and 20% epiphrenic. Zenker's diverticulum is well treated with endoscopy (efficacy around 80%, complications around 5%) (1). For medio or epihrenic diverticulum, the classic treatment is surgery (diverticulectomy with or without anti-reflux surgery) but is associated with 33% morbidity and 9% mortality (2). Recently another technique involving magnet was described (3). Five patients were treated with success.

Considering the surgical risk, other techniques need to be evaluated. Using the Endomina device, sutures can be apposed between the foot of the diverticulum and the esophageal lumen. If necessary the bridge between the diverticulum and the esophagus can be cut with needle knife as described in Zenker's diverticulum treatment.

02

Conditions studied

  • Oesophageal Disease

Keywords

  • endoscopy
  • mini invasive
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Symptomatic medio or epiphrenic diverticulum.
  2. Age between 18-80 years;
  3. Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study specific procedures such as: clinical assessment, endoscopy, radiography, as well as laboratory investigations;
  4. Must be able to understand and be willing to provide written informed consent;
  5. Must live within 75 km of the treatment site;

Exclusion criteria

Exclusion Criteria:

  1. Achalasia and any other esophageal motility disorders.
  2. Severe esophagitis
  3. Gastro-duodenal ulcer
  4. Severe renal, hepatic, pulmonary disease or cancer;
  5. GI stenosis or obstruction;
  6. Pregnancy, breastfeeding or willing to become pregnant in the coming 18 months;
  7. Anticoagulant therapy;
  8. Currently participating in other study
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Intervention

    Device: Endomina

Interventions

  • DeviceEndomina

    Suturing system then cutting the bridge between the diverticulum and the esophagus.

05

What researchers measure

Primary outcomes

  1. Incidence of all Adverse Device Effects

    Safety will be characterized by the incidence of all Adverse Device Effects

    Time frame: one year from procedure

Secondary outcomes

  1. Dysphagia

    Efficacy will be measured by the Dakkak and Bennett score of Dysphagia (Score 0 - no dysphagia to 4 - aphagia)

    Time frame: one year from procedure

06

Study locations

1 site
  • Gastroenterology Department Erasme Hospital
    Brussels, 1070, Belgium
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03609073
Lead sponsor
Erasme University Hospital
Responsible party
Sponsor
First posted
Aug 1, 2018
Start date
Mar 6, 2018
Primary completion
Oct 25, 2021
Completion
Oct 25, 2021
Last update
Nov 24, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion